• Molecular NamePapaverine
  • SynonymChlorhydrate de Papaverine; Papavarine Chlorhydrate; Papaverin; Papaverine Chlorohydrate; Papaverine Hcl; Papaverine Hydrochloride; Papaverine Monohydrochloride; Papaverinium Chloride
  • Weight339.391
  • Drugbank_IDDB01113
  • ACS_NO58-74-2
  • Show 3D model
  • LogP (experiment)2.95
  • LogP (predicted, AB/LogP v2.0)3.03
  • pka6.4
  • LogD (pH=7, predicted)2.95
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-4.19
  • LogSw (predicted, AB/LogsW2.0)0.03
  • Sw (mg/ml) (predicted, ACD/Labs)0.02
  • No.of HBond Donors0
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds6
  • TPSA49.81
  • StatusFDA approved
  • AdministrationOral, intravenous, intramuscular, rectal,[5] intracavernosal
  • PharmacologyAn opium alkaloid used primarily in the treatment of visceral spasm, vasospasm (especially those involving the heart and the brain), and occasionally in the treatment of erectile dysfunction.
  • Absorption_value90.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability28.0
  • Protein binding90.0
  • Volume of distribution (VD)0.99~1.52 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic
  • Half life7 h, but there is wide variation and a biological half-life of 1 to 2 h is also reported.
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A